Medsir

This study tests a drug called Trastuzumab-Deruxtecan (T-DXd) in 28 people with HER2-low breast cancer that has spread to the brain. The goal is to see if the drug can shrink brain tumors and tumors elsewhere in the body. Participants receive the drug intravenously, and doctors m…

This study tests whether a chemotherapy-free combination of drugs (trastuzumab, pertuzumab, and T-DM1) can effectively treat HER2-positive early breast cancer. About 393 participants will receive these drugs to see if the cancer disappears completely. The goal is to avoid chemoth…

This study aimed to test a combination of three drugs (zimberelimab, domvanalimab, and sacituzumab govitecan) as a first treatment for people with advanced triple-negative breast cancer that shows a specific marker (PD-L1 positive). The goal was to see if the combo could shrink t…

This study tests a two-step treatment for people with HER2-positive breast cancer that has spread or cannot be removed. First, patients receive a strong drug called trastuzumab deruxtecan. Then, they switch to a maintenance combination of two other drugs (trastuzumab and pertuzum…

This study tests a combination of two drugs, Debio 0123 and sacituzumab govitecan, in people with advanced breast cancer that has not responded to previous treatments. The goal is to find the safest dose and see if the combination can shrink tumors. About 76 participants will tak…

This study tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy can eliminate all signs of cancer in people with early-stage triple-negative breast cancer before they have surgery. About 31 participants with small tumors (1 to 2.5 cm) that haven't sp…

This study tests a new drug (MEN1611) combined with chemotherapy (eribulin) in people with advanced breast cancer that has specific genetic changes (PIK3CA/PTEN). The goal is to see if the combination can shrink tumors or stop them from growing. The trial includes 14 adults whose…